Jalen Hurts’ blood-clot diagnosis raises new questions about NFL medical safeguards

Philadelphia Eagles coach Nick Sirianni declined to revisit the medical decisions surrounding Jalen Hurts on October 22, directing questions toward the NFL and the players’ union. That refusal did not close the issue. It clarified where the public disagreement now sits: Hurts’ doctors and representatives say his prognosis is very good, while the league and union remain divided over whether the process that cleared him to play received an adequate review.

A joint statement from the Eagles and Hurts’ agent, Nicole Lynn, said specialists initially found a superficial-vein thrombosis in his left calf in London. Further testing later identified a deep-vein thrombosis and bilateral pulmonary emboli—blood clots in both lungs. The statement said Hurts was clinically stable, had no significant functional limitations and was expected to make a full recovery. He is taking anticoagulants and cannot participate in contact activity, including football, while on that medication.

The timeline from calf injury to pulmonary emboli

The publicly described timeline begins October 4, when Hurts was cleated in the calf during Philadelphia’s game against the Los Angeles Rams. The team said he sought treatment after practice on October 8 and again the next day. An ultrasound in London on October 10 found what the Eagles described as a superficial clot. Team doctors and London specialists concluded that activity and mobility were important and cleared him to face Jacksonville on October 11, with follow-up imaging recommended within 72 hours.

Hurts played every offensive snap in the London game. Reports that he had been awake for more than 30 hours before kickoff became part of the early backlash, but the NFL disputes that account. League executive Jeff Miller said Hurts returned to the team hotel and slept for roughly seven or eight hours. The disagreement is important because it shows why the final account should be built from medical records and interviews, not viral summaries.

After the team returned to Philadelphia, Hurts continued treatment. A follow-up ultrasound on October 14 showed movement in the small clot, according to the Eagles. He was ruled out the next day and placed on injured reserve October 17. The more serious diagnosis was announced October 19 after additional testing and monitoring.

What the diagnosis means—and what outsiders cannot know

The medical distinction matters. The Centers for Disease Control and Prevention describes deep-vein thrombosis as a clot that forms in a deep vein, usually in the leg. A pulmonary embolism can occur when part of a clot breaks away and travels to the lungs. Those conditions can be life-threatening, but the clinicians quoted in current coverage are not treating Hurts and cannot determine from outside the case exactly how his condition progressed. The most specific prognosis remains the one supplied by his medical team through the joint statement: expected full recovery and no anticipated long-term effects.

The league and union are describing different levels of review

NFL Commissioner Roger Goodell said league protocols were followed and that the NFL would welcome a union review. Chief medical officer Dr. Allen Sills defended the Eagles’ staff, saying league officials had been in contact with team doctors, trainers and the Cleveland Clinic in London. The NFL’s position is that appropriate care can still be followed by a worse medical outcome.

The NFL Players Association is asking for more than that assurance. In a statement carried by multiple outlets, the union said it was unaware of an NFL investigation into Hurts’ care and had previously been told that the league did not plan to review it. The union called for a full investigation before conclusions are drawn. That is a request for fact-finding, not proof that the Eagles, their clinicians or the league violated a rule or medical standard.

Sirianni has consistently said he trusts the medical professionals and that player health comes first. On October 22, he said he cared deeply about Hurts but would focus his news conference on the Eagles’ upcoming game. His decision not to answer additional questions leaves the league’s defense and the union’s demand as the two clearest institutional positions.

Why this is a labor and player-safety story

The stakes extend beyond one roster move. Hurts is one of the league’s most visible Black quarterbacks, but he is also an employee whose career depends on medical judgments made inside a high-pressure workplace. Players need confidence that a clearance reflects health alone; clubs and clinicians need room to explain decisions without turning private medical information into spectacle. A credible review can protect both interests by separating documented decisions from assumptions about motive.

The unresolved questions are practical: who evaluated Hurts, what information each decision-maker had before the London game and return flight, what follow-up plan was ordered, and whether the league’s internal check meets the union’s standard for an investigation. Until those facts are documented, the responsible conclusion is limited. Hurts’ recovery is the priority, the league says its procedures worked, and the union believes that claim still requires independent scrutiny.